DK3247707T3 - 4-methylsulfonyl-substituerede piperidin urea-forbindelser, nyttige til behandling af hjertelidelser som dilateret kardiomyopati (dcm) - Google Patents

4-methylsulfonyl-substituerede piperidin urea-forbindelser, nyttige til behandling af hjertelidelser som dilateret kardiomyopati (dcm) Download PDF

Info

Publication number
DK3247707T3
DK3247707T3 DK16702652.5T DK16702652T DK3247707T3 DK 3247707 T3 DK3247707 T3 DK 3247707T3 DK 16702652 T DK16702652 T DK 16702652T DK 3247707 T3 DK3247707 T3 DK 3247707T3
Authority
DK
Denmark
Prior art keywords
dcm
treatment
compounds useful
dilated cardiomyopathy
urea compounds
Prior art date
Application number
DK16702652.5T
Other languages
Danish (da)
English (en)
Inventor
Johan Oslob
Danielle Aubele
Jae Kim
Robert Mcdowell
Yonghong Song
Arvinder Sran
Min Zhong
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Application granted granted Critical
Publication of DK3247707T3 publication Critical patent/DK3247707T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16702652.5T 2015-01-22 2016-01-21 4-methylsulfonyl-substituerede piperidin urea-forbindelser, nyttige til behandling af hjertelidelser som dilateret kardiomyopati (dcm) DK3247707T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22
PCT/US2016/014365 WO2016118774A1 (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Publications (1)

Publication Number Publication Date
DK3247707T3 true DK3247707T3 (da) 2023-07-03

Family

ID=55275230

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16702652.5T DK3247707T3 (da) 2015-01-22 2016-01-21 4-methylsulfonyl-substituerede piperidin urea-forbindelser, nyttige til behandling af hjertelidelser som dilateret kardiomyopati (dcm)

Country Status (36)

Country Link
US (1) US9925177B2 (enExample)
EP (2) EP4234017B1 (enExample)
JP (1) JP6712275B2 (enExample)
KR (3) KR102688851B1 (enExample)
CN (3) CN118164961A (enExample)
AU (4) AU2016209200B2 (enExample)
BR (1) BR112017015627B1 (enExample)
CA (1) CA2974370C (enExample)
CL (1) CL2017001871A1 (enExample)
CO (1) CO2017008398A2 (enExample)
CR (1) CR20170370A (enExample)
DK (1) DK3247707T3 (enExample)
DO (2) DOP2017000166A (enExample)
EA (1) EA036923B1 (enExample)
EC (1) ECSP17054181A (enExample)
ES (2) ES2953480T3 (enExample)
FI (1) FI3247707T3 (enExample)
GT (1) GT201700163A (enExample)
HR (1) HRP20230737T1 (enExample)
HU (1) HUE063410T2 (enExample)
IL (6) IL313678A (enExample)
LT (1) LT3247707T (enExample)
MX (3) MX394704B (enExample)
MY (1) MY203427A (enExample)
PE (2) PE20212253A1 (enExample)
PH (2) PH12017501279B1 (enExample)
PL (1) PL3247707T3 (enExample)
PT (1) PT3247707T (enExample)
RS (1) RS64432B1 (enExample)
SG (2) SG11201705928XA (enExample)
SI (1) SI3247707T1 (enExample)
SM (1) SMT202300259T1 (enExample)
TN (1) TN2017000320A1 (enExample)
UA (1) UA119905C2 (enExample)
WO (1) WO2016118774A1 (enExample)
ZA (1) ZA201704777B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
MA54677A (fr) 2018-02-01 2021-11-17 Myokardia Inc Composés pyrazoles et leur préparation
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
US20210053939A1 (en) 2019-07-16 2021-02-25 MyoKardia, Inc. Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
JP7832128B2 (ja) * 2020-06-15 2026-03-17 マイオカーディア，インク 心房機能不全の治療
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
WO2023049919A1 (en) * 2021-09-27 2023-03-30 The Trustees Of The University Of Pennsylvania Inhibitors of molluscum contagiosum infection and methods using the same
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117882A2 (en) 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US7507735B2 (en) * 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2011059021A1 (ja) * 2009-11-11 2011-05-19 大日本住友製薬株式会社 ８－アザビシクロ［３．２．１］オクタン－８－カルボキサミド誘導体

Also Published As

Publication number Publication date
DOP2017000166A (es) 2017-10-15
CA2974370C (en) 2023-10-31
KR20170113578A (ko) 2017-10-12
EA036923B1 (ru) 2021-01-15
US20160243100A1 (en) 2016-08-25
CN107428719B (zh) 2020-03-27
UA119905C2 (uk) 2019-08-27
EP3247707A1 (en) 2017-11-29
JP2018502883A (ja) 2018-02-01
AU2016209200B2 (en) 2020-07-02
AU2023200361B2 (en) 2024-08-22
CL2017001871A1 (es) 2018-04-13
EA201791656A1 (ru) 2017-11-30
MX2017009540A (es) 2017-10-20
MX2021010778A (es) 2022-08-11
EP4234017A3 (en) 2023-10-18
US9925177B2 (en) 2018-03-27
HUE063410T2 (hu) 2024-01-28
CR20170370A (es) 2017-10-20
KR102585550B1 (ko) 2023-10-10
AU2024266781A1 (en) 2024-12-12
AU2016209200A1 (en) 2017-08-10
IL279247A (en) 2021-01-31
MX394704B (es) 2025-03-24
HRP20230737T1 (hr) 2023-10-13
MY203427A (en) 2024-06-27
BR112017015627A2 (pt) 2018-03-13
CN111393414B (zh) 2024-05-07
KR20240119163A (ko) 2024-08-06
ES3075390T3 (en) 2026-08-04
IL253552A0 (en) 2017-09-28
CA2974370A1 (en) 2016-07-28
ES2953480T3 (es) 2023-11-13
KR102688851B1 (ko) 2024-07-29
HK1246775A1 (en) 2018-09-14
WO2016118774A1 (en) 2016-07-28
EP4234017B1 (en) 2026-04-15
PL3247707T3 (pl) 2023-12-11
IL313678A (en) 2024-08-01
PE20171511A1 (es) 2017-10-20
DOP2022000172A (es) 2022-09-30
KR20230145504A (ko) 2023-10-17
PH12017501279A1 (en) 2018-01-29
IL295547A (en) 2022-10-01
IL253552B (en) 2019-12-31
MX385960B (es) 2025-03-18
PH12021553074A1 (en) 2023-03-06
LT3247707T (lt) 2023-08-25
CN111393414A (zh) 2020-07-10
MX2022007040A (es) 2022-06-24
SI3247707T1 (sl) 2023-10-30
SG10201913047UA (en) 2020-02-27
SMT202300259T1 (it) 2023-09-06
PE20212253A1 (es) 2021-11-24
PT3247707T (pt) 2023-08-31
CN118164961A (zh) 2024-06-11
AU2020244490B2 (en) 2022-12-01
JP6712275B2 (ja) 2020-06-17
FI3247707T3 (fi) 2023-08-22
AU2023200361A1 (en) 2023-02-23
ECSP17054181A (es) 2019-02-28
RS64432B1 (sr) 2023-09-29
AU2020244490A1 (en) 2020-10-29
PH12017501279B1 (en) 2023-06-16
SG11201705928XA (en) 2017-08-30
ZA201704777B (en) 2023-07-26
BR112017015627B1 (pt) 2022-11-16
NZ734020A (en) 2023-11-24
IL286369A (en) 2021-10-31
GT201700163A (es) 2018-10-18
EP4234017A2 (en) 2023-08-30
CN107428719A (zh) 2017-12-01
TN2017000320A1 (en) 2019-01-16
IL271034A (en) 2020-01-30
CO2017008398A2 (es) 2017-10-31
EP3247707B1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
SI3247707T1 (sl) S 4-metilsulfonilom substituirane spojine piperidina sečnine, uporabne za zdravljenje srčnih motenj, kot je dilatacijska kardiomiopatija (dcm)
DK3577110T3 (da) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer
IL256898A (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
HUE053819T2 (hu) Ciklikus dinukleotid-vegyületek
DK3341355T3 (da) (s)-3-amino-4-(difluormethylenyl)cyclopent-1-en-1-carboxylsyre og tilhørende forbindelser som gaba-aminotransferaseinaktivatorer til behandling af epilepsi, afhængighed og hepatocellulært karcinom
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
DK3407888T3 (da) Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser
LT3159409T (lt) Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui
EP2970306A4 (en) SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
EP3507007A4 (en) PHOTOACTIVE CATALYST COMPOSITIONS
DK3230281T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
EP2681216A4 (en) SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
DK3230278T3 (da) Hidtil ukendte methyl-piperidin-forbindelser, som er anvendelige til inhibering af mikrosomale prostaglandin-e2-syntase-1
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK3099333T3 (da) Bag3 som mål for behandling af hjertesvigt
DK3524255T3 (da) Sammensætning til behandling af acne
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
EP3494119A4 (en) CONNECTIONS AND COMPOSITIONS AND USES THEREOF
EA201300946A1 (ru) Асимметричные мочевины и их медицинское применение
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
EP3552017A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS
IL261575B (en) Electricity generation process
HUE053263T2 (hu) Több elársztott mosófejjel ellátott, többszintes gázmosó